Bibliographie
BRINK C. et al. (2003) : Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev., 55, 195-227.
CARSIN A. et al. (2012) : Physiopathologie de l'asthme avec intolérance à l'aspirine. Concepts classiques et nouvelles voies métaboliques d'intérêt. Revue des Maladies Respiratoires, 29, 118-127.
ENCINAS S. et al. (1998) : Phototoxicity associated with Diclofenac: A photophysical, photochemical, and photobiological study on the drug and its photoproducts. Chem. Res. Toxicol., 11, 946-952.
JOHNSTON P.G. et al (2012) : Evidence-based use of Indomethacin and Ibuprofen in the neonatal intensive care unit. Clinics in Perinatology, 39, 111-136.
JOUZEAU J.-Y. et al (2004) : Pharmacologie et classification des inhibiteurs de la cyclooxygénase, Gastroenterol. Clin. Biol., 28, C7-C17.
KYRIKOU I. et al. (2004) : Effects of non-steroid anti-inflammatory drugs in membrane bilayers. Chemistry and Physics of Lipids 132, 157-169.
LÉVESQUE, H., LAFONT, O. (2000) : L'aspirine à travers les siècles: Rappel historique. La Revue de Médecine Interne, 21, Supplément 1, 8-17.
LUONG, C. et al. (1996) : Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Structural Biology, 3(11), 927-933.
MAGNAN A. (2006) : Allergies aux AINS, Revue des Maladies Respiratoires, 23, 10S66-10S69.
MORENO M.M. et al. (2009) : The membrane-activity of Ibuprofen, Diclofenac, and Naproxen: A physico-chemical study with lecithin phospholipids. Biochimica et Biophysica Acta, 1788, 1296-1303.
MUSA K.A.K. et al. (2007) : Mechanism of photoinduced decomposition of Ketoprofen. J. Med. Chem., 50, 1735-1743.
NAKAJIMA A. et al. (2005) : Determination of free radicals generated from light exposed ketoprofen. Journal of Photochemistry and Photobiology A: Chemistry, 174, 89–97.
PATRIGNANI P., PATRONO C. (2015) : Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochimica et Biophysica Acta, 1851, 422-432.
PATRONO C. (2015) : The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. Journal of the American College of Cardiology, 66, 74-85.
PICOT D., LOLL P. J., GARAVITO R. M. (1994) : The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature, 367(6460), 243-249.
PILLON F. (2014) : Les anti-inflammatoires non stéroïdiens. Actualités pharmaceutiques, 534, 43-46.
RAISON-PEYRON N. (2007) : Hypersensibilité / Intolérance aux AINS : multiples aspects cliniques ? Revue française d'allergologie et d'immunologie clinique, 47, S55-S59.
ROWLINSON S.W. et al. (2003) : A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385. J. Biol. Chem., 278(46), 45763-45769.
SIDHU R.S. et al (2010) : Comparison of Cyclooxygenase-1 Crystal Structures: Cross-Talk between Monomers Comprising Cyclooxygenase-1 Homodimers. Biochemistry, 49, 7069-7079
STEINBERG G.R. et al. (2013) : AMPK: mediating the metabolic effects of salicylate-based drugs? Trends in Endocrinology and Metabolism, Vol. 24(10), 481-487.
TOMISATO W. et al. (2004) : Membrane permeabilization by non-steroidal anti-inflammatory drugs, Biochem. Biophys. Res. Communic. 323, 1032–1039.
VANE J.R., BOTTING R.M. (2003) : The mechanism of action of aspirin. Thrombosis Research, 110, 255-258.
WANG J.L. et al. (2010) : The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: The first clinical candidate. Bioorganic & Medicinal Chemistry Letters, 20, 7155–7158.
XU S. et al. (2014) : Oxicams bind in a novel mode to the Cyclooxygenase active site via a two-water-mediated H-bonding network. J. Biol. Chem., 289(10), 6799–6808.
YAMAKAWA N. et al. (2014) : Structure–activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity. Bioorganic & Medicinal Chemistry 22, 2529–2534
